dc.contributor.author |
Adam, Ahmed
|
|
dc.contributor.author |
Manda, S.O.M. (Samuel)
|
|
dc.date.accessioned |
2013-05-30T06:34:25Z |
|
dc.date.available |
2013-05-30T06:34:25Z |
|
dc.date.issued |
2013-06 |
|
dc.description.abstract |
The incidence of prostate cancer among South African men is just as significant as it is worldwide [1,2].
Although the role of the prostate cancer antigen 3 (PCA3) assay in predicting biopsy outcome has proven
beneficial in a South African context [3], the assessment of its role incorporated into a prostate cancer risk
calculator has not yet been explored on the continent of Africa. We aimed to assess the performance of the
PCA3-incorporated Chun nomogram [4] and to compare its performance with other contemporary risk
calculators. |
en_US |
dc.description.librarian |
hb2013 |
en_US |
dc.description.uri |
http://www.europeanurology.com/article/S0302-2838(13)00139-5 |
en_US |
dc.identifier.citation |
Adam, A & Manda, SO 2013, 'How well does the PCA3–incorporated chun nomogram perform in predicting prostate biopsy outcome among South African men?', European Urology, vol. 63, no. 6, pp. e67-e86. |
en_US |
dc.identifier.issn |
0302-2838 (print) |
|
dc.identifier.issn |
1421-993x (online) |
|
dc.identifier.other |
10.1016/j.eururo.2013.02.027 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/21574 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Elsevier |
en_US |
dc.rights |
© 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
en_US |
dc.subject |
Prostate cancer |
en_US |
dc.subject |
South African men |
en_US |
dc.subject |
PCA3–incorporated Chun Nomogram |
en_US |
dc.title |
How well does the PCA3–incorporated chun nomogram perform in predicting prostate biopsy outcome among South African men? |
en_US |
dc.type |
Postprint Article |
en_US |